Matinas BioPharma (MTNB) Shares Down 7.4%

Share on StockTwits

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) fell 7.4% on Friday . The stock traded as low as $1.10 and last traded at $1.13. 1,580,112 shares were traded during mid-day trading, an increase of 30% from the average session volume of 1,219,598 shares. The stock had previously closed at $1.22.

Separately, Roth Capital initiated coverage on shares of Matinas BioPharma in a report on Monday, February 11th. They set a “buy” rating and a $4.75 target price on the stock.

Several hedge funds have recently made changes to their positions in the company. IFP Advisors Inc raised its holdings in Matinas BioPharma by 222.0% in the 4th quarter. IFP Advisors Inc now owns 1,775,000 shares of the company’s stock valued at $1,083,000 after buying an additional 1,223,828 shares during the period. Private Advisor Group LLC raised its holdings in Matinas BioPharma by 100.4% in the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after buying an additional 24,978 shares during the period. Renaissance Technologies LLC raised its holdings in Matinas BioPharma by 325.6% in the 3rd quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $124,000 after buying an additional 103,200 shares during the period. Virtu Financial LLC purchased a new stake in Matinas BioPharma in the 4th quarter valued at about $39,000. Finally, Northern Trust Corp raised its holdings in Matinas BioPharma by 18.9% in the 4th quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock valued at $109,000 after buying an additional 29,072 shares during the period.

ILLEGAL ACTIVITY NOTICE: This report was first published by Highlight Press and is the property of of Highlight Press. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://highlightpress.com/2019/03/24/matinas-biopharma-mtnb-shares-down-7-4.html.

About Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Read More: Discover Your Risk Tolerance

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.